<DOC>
	<DOCNO>NCT01383785</DOCNO>
	<brief_summary>Aims : ( prove ) The distal injection IIb IIIa platelet receptor blocker thrombus occlusion well normal injection primary percutaneous intervention ( PCI ) treatment acute myocardial infarction . Using modification injection method investigator achieve less microvascular damage reduction infarct size significant improvement outcome six month .</brief_summary>
	<brief_title>Thrombus Aspiration OcLuded Coronary Artery Enhanced With Distal Injection Of Abciximab</brief_title>
	<detailed_description>There evidence utilization aspiration catheter ( Indication class IIb level evidence B European Guidelines ) intravenous abciximab ( indication Class IIa level evidence A European Guidelines ) primary PTCA . Direct intracoronary injection abciximab get small infarct size intravenous injection . The hypothesis study direct distal injection abciximab aspiration catheter well proximal intracoronary injection reduction infarct size microvascular damage quantify Magnetic resonance ( MR ) 6 month mortality .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Myocardial infarction patient 3 12 hour symptom onset Hemodynamic instability TIMI flow 2 3 Life expectance le 6 month Contraindication AAS , clopidogrel abciximab Severe tortuosity occlude vessel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Primary PTCA</keyword>
	<keyword>Thrombus Aspiration Catheter</keyword>
	<keyword>Intracoronary Abciximab</keyword>
</DOC>